Skip to main content
Top
Published in: Clinical and Experimental Medicine 3/2010

01-09-2010 | Original Article

Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy

Authors: Mariusz Nowak, Tomasz Wielkoszyński, Bogdan Marek, Beata Kos-Kudła, Elżbieta Świętochowska, Lucyna Siemińska, Jacek Karpe, Dariusz Kajdaniuk, Joanna Głogowska-Szeląg, Katarzyna Nowak

Published in: Clinical and Experimental Medicine | Issue 3/2010

Login to get access

Abstract

The aim of this study was to evaluate the ferric-reducing ability of serum (FRAS), paraoxonase 1 (PON1), ceruloplasmin serum oxidase activity and hsCRP level in patients with type1 diabetes mellitus without and with diabetic retinopathy. The study was performed in 76 patients with type 1 diabetes mellitus, 35 without diabetic retinopathy (group 1) and 41 with preproliferative and proliferative retinopathy (group 2). Control group consisted of 35 nondiabetic, age-, gender-, body mass-matched healthy volunteers who came to the outpatient clinic for a routine health check-up. We evaluated FRAS using the method described by Benzie and Strain; PON1 by kinetic spectrophotometric assay with paraoxon as substrate and ceruloplasmin using its oxidative activity with 3-phenylenodiamine as substrate. CRP was measured with a high sensitive enzyme immunoassay. PON1 activity was significantly decreased in patients with diabetic retinopathy (227.66 ± 123.57 U/l) when compared with control (312.04 ± 129.77 U/l). FRAS was significantly decreased in group 2 (439.33 ± 79.87 μmol/l) when compared with group 1 (522.79 ± 167.56 μmol/l) and control (529.80 ± 81.99 μmol/l). Ceruloplasmin activity was significantly elevated in group 1 (58.36 ± 22.56 U/g protein) when compared with control (45.22 ± 14.96 U/g protein). We have found significant increase in hsCRP level in group 2 (3.71 ± 2.47 mg/l) when compared with group 1 (1.75 ± 1.01 mg/l) and control (0.57 ± 0.46 mg/l). The PON1/CRP ratio in control group was significantly increased when compared with diabetic patients and was significantly decreased in group 2 compared with group 1. We have not found gender-dependent difference in studied parameters in both control and in study groups. We have found tendency to decrease the serum activity of FRAS and hsCRP in elder patients but the difference was significant only in group 2. FRAS and PON 1 activity is decreased in patients with type 1 diabetes mellitus with presence of diabetic retinopathy which confirms that oxidative stress could play a role in pathogenesis of diabetic retinopathy. Significantly elevated levels of hsCRP in diabetic patients with the presence of diabetic retinopathy compared with patients without diabetic retinopathy providing a link between inflammation and the development of microvascular complication of diabetes. Because of the significant difference in PON1/CRP ratio between patients without and with the presence of diabetic retinopathy, it seems that PON1:CRP ratio may be used as a biochemical marker for progression of retinopathy. The link between the antioxidant concentration, inflammation and the development of diabetes complications needs further longitudinal studies in order to confirm our findings.
Literature
1.
go back to reference The Diabetes Control Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Eng J Med 329:977–986CrossRef The Diabetes Control Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Eng J Med 329:977–986CrossRef
2.
go back to reference D’Amore P (1994) Mechanisms of retinal and choroidal neovascularisation. Invest Ophth Vis Sci 35:3974–3979 D’Amore P (1994) Mechanisms of retinal and choroidal neovascularisation. Invest Ophth Vis Sci 35:3974–3979
3.
go back to reference Nowak M, Wielkoszyński T, Marek B, Świętochowska E, Kos-Kudła B, Siemińska L, Kajdaniuk D, Głogowska-Szeląg J, Nowak K (2008) Comparison of the levels of hepatocyte growth factor in serum with grades of retinopathy in patients with type 1 diabetes mellitus. Endokrynol Pol 59:2–5PubMed Nowak M, Wielkoszyński T, Marek B, Świętochowska E, Kos-Kudła B, Siemińska L, Kajdaniuk D, Głogowska-Szeląg J, Nowak K (2008) Comparison of the levels of hepatocyte growth factor in serum with grades of retinopathy in patients with type 1 diabetes mellitus. Endokrynol Pol 59:2–5PubMed
4.
go back to reference Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H (1990) A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) I: causes and death rates. Diabetologia 33:538–541CrossRefPubMed Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H (1990) A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) I: causes and death rates. Diabetologia 33:538–541CrossRefPubMed
5.
go back to reference Frank RN (1994) The aldose reductase controversy. Diabetes 43:169–172PubMed Frank RN (1994) The aldose reductase controversy. Diabetes 43:169–172PubMed
6.
go back to reference Forester JV, Knott RM, Mc Intosh LC (1993) Pathogenesis of proliferative diabetic retinopathy and maculopathy. Elsevier, Amsterdam, pp 178–191 Forester JV, Knott RM, Mc Intosh LC (1993) Pathogenesis of proliferative diabetic retinopathy and maculopathy. Elsevier, Amsterdam, pp 178–191
7.
go back to reference Grisanti S, Heimann K, Wiedemann P (1994) Immune response to specific molecules of the retina in proliferative vitroretinal disorders. Graefes Arch Clin Exp Ophthalmol 232:302–307CrossRefPubMed Grisanti S, Heimann K, Wiedemann P (1994) Immune response to specific molecules of the retina in proliferative vitroretinal disorders. Graefes Arch Clin Exp Ophthalmol 232:302–307CrossRefPubMed
8.
go back to reference Mokini Z, Chiarelli F (2006) The molecular basis of diabetic microangiopathy. Pediatr Endocrinol Rev 4:138–152PubMed Mokini Z, Chiarelli F (2006) The molecular basis of diabetic microangiopathy. Pediatr Endocrinol Rev 4:138–152PubMed
9.
go back to reference Siemianowicz K, Gminski J, Telega A, Wójcie A, Posielezna B, Grafowska-Bochenek R, Francuz T (2004) Blood antioxidant parameters in patients with diabetic retinopathy. Int J Mol Med 14:433–437PubMed Siemianowicz K, Gminski J, Telega A, Wójcie A, Posielezna B, Grafowska-Bochenek R, Francuz T (2004) Blood antioxidant parameters in patients with diabetic retinopathy. Int J Mol Med 14:433–437PubMed
10.
go back to reference Maiese K, Morhan SD, Chong ZZ (2007) Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res 41:63–71CrossRef Maiese K, Morhan SD, Chong ZZ (2007) Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res 41:63–71CrossRef
11.
go back to reference Tomas M, Latorre G, Senti M, Marrugat J (2004) The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis. Rev Esp Cardiol 57:557–569CrossRefPubMed Tomas M, Latorre G, Senti M, Marrugat J (2004) The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis. Rev Esp Cardiol 57:557–569CrossRefPubMed
12.
go back to reference Frieden E (1980) Caeruloplasmin: a multi-functional metalloprotein of vertebrate plasma. Ciba Found Symp 79:93–124PubMed Frieden E (1980) Caeruloplasmin: a multi-functional metalloprotein of vertebrate plasma. Ciba Found Symp 79:93–124PubMed
13.
14.
go back to reference Correale M, Brunetti ND, De Gennaro L, Di Biase M (2008) Acute phase proteins in atherosclerosis (acute coronary syndrome). Cardiovasc Hematol Agents Med Chem 6:272–277CrossRefPubMed Correale M, Brunetti ND, De Gennaro L, Di Biase M (2008) Acute phase proteins in atherosclerosis (acute coronary syndrome). Cardiovasc Hematol Agents Med Chem 6:272–277CrossRefPubMed
15.
go back to reference Izuora KE, Chase HP, Jackson WE, Coll JR, Osberg IM, Gottlieb PA, Rewers MJ, Garg SK (2005) Inflammatory markers and diabetic retinopathy in type 1 diabetes. Diabetes Care 28:714–715CrossRefPubMed Izuora KE, Chase HP, Jackson WE, Coll JR, Osberg IM, Gottlieb PA, Rewers MJ, Garg SK (2005) Inflammatory markers and diabetic retinopathy in type 1 diabetes. Diabetes Care 28:714–715CrossRefPubMed
16.
go back to reference Benzie JF, Strain JJ (1996) The ferric reducing ability of plasma (FRAP) as a measure of „antioxidant power”: the FRAP assay. Anal Biochem 239:70–76CrossRefPubMed Benzie JF, Strain JJ (1996) The ferric reducing ability of plasma (FRAP) as a measure of „antioxidant power”: the FRAP assay. Anal Biochem 239:70–76CrossRefPubMed
17.
go back to reference Eckerson HW, Romson J, Wyte C, La Du BN (1983) The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 35:214–227PubMed Eckerson HW, Romson J, Wyte C, La Du BN (1983) The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 35:214–227PubMed
18.
go back to reference Richterich R, Temperli A, Aebi H (1962) The heterogeneity of ceruloplasmin: isolation and characterization of 2 cuproproteins from human serum. Biochim Biophys Acta 29:240–251CrossRef Richterich R, Temperli A, Aebi H (1962) The heterogeneity of ceruloplasmin: isolation and characterization of 2 cuproproteins from human serum. Biochim Biophys Acta 29:240–251CrossRef
19.
go back to reference Nowak M, Świętochowska E, Wielkoszyński T, Marek B, Karpe J, Górski J, Głogowska-Szeląg J, Kos-Kudła B, Ostrowska Z (2003) Changes in blood antioxidants and several lipid peroxidation products in women with age-related macular degeneration. Eur J Ophthalmol 13:281–286PubMed Nowak M, Świętochowska E, Wielkoszyński T, Marek B, Karpe J, Górski J, Głogowska-Szeląg J, Kos-Kudła B, Ostrowska Z (2003) Changes in blood antioxidants and several lipid peroxidation products in women with age-related macular degeneration. Eur J Ophthalmol 13:281–286PubMed
20.
go back to reference Chen C, Arjomandi M, Balmes J, Tanger I, Holland N (2007) Effects of chronic and acute ozone exposure on lipid peroxidation and antioxidant capacity in healthy young adults. Environ Health Perspect 115:1732–1737CrossRefPubMed Chen C, Arjomandi M, Balmes J, Tanger I, Holland N (2007) Effects of chronic and acute ozone exposure on lipid peroxidation and antioxidant capacity in healthy young adults. Environ Health Perspect 115:1732–1737CrossRefPubMed
21.
go back to reference Rodrigo R, Prat H, Passalacqua W, Araba J, Bachler JP (2008) Decrease in oxidative stress through supplementation of vitamins C and E is associated with a reduction in blood pressure in patients with essential hypertension. Clin Sci (Lond) 114:625–634CrossRef Rodrigo R, Prat H, Passalacqua W, Araba J, Bachler JP (2008) Decrease in oxidative stress through supplementation of vitamins C and E is associated with a reduction in blood pressure in patients with essential hypertension. Clin Sci (Lond) 114:625–634CrossRef
22.
go back to reference Jones AF, Winkles JW, Jennings PE, Florkowski CM, Lunec J, Barnett AH (1988) Serum antioxidant activity in diabetes mellitus. Diabetes Res 7:89–92PubMed Jones AF, Winkles JW, Jennings PE, Florkowski CM, Lunec J, Barnett AH (1988) Serum antioxidant activity in diabetes mellitus. Diabetes Res 7:89–92PubMed
23.
go back to reference Srivatsan R, Das S, Gadde R, Manoj-Kumar K, Taduri K, Rao N, Ramesh B, Baharani A, Shah K, Kamireddy SC, Priyatham G, Balakumaran TA, Balakumaran SS, Kamath A, Rao A (2009) Antioxidants and lipid peroxidation status in diabetic patients with and without complications. Arch Iran Med 12:121–127PubMed Srivatsan R, Das S, Gadde R, Manoj-Kumar K, Taduri K, Rao N, Ramesh B, Baharani A, Shah K, Kamireddy SC, Priyatham G, Balakumaran TA, Balakumaran SS, Kamath A, Rao A (2009) Antioxidants and lipid peroxidation status in diabetic patients with and without complications. Arch Iran Med 12:121–127PubMed
24.
go back to reference Memişoğullari R, Bakan E (2004) Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with Type 2 diabetes mellitus. J Diabetes Complicat 18:193–197CrossRefPubMed Memişoğullari R, Bakan E (2004) Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with Type 2 diabetes mellitus. J Diabetes Complicat 18:193–197CrossRefPubMed
25.
go back to reference Abou-Seif MA, Youssef MA (2004) Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 346:161–170CrossRefPubMed Abou-Seif MA, Youssef MA (2004) Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 346:161–170CrossRefPubMed
26.
go back to reference Siemianowicz K, Francuz T, Gminski J, Telega A, Syzdol M (2005) Endothelium dysfunction in patients with diabetic retinopathy. Int J Mol Med 15:459–462PubMed Siemianowicz K, Francuz T, Gminski J, Telega A, Syzdol M (2005) Endothelium dysfunction in patients with diabetic retinopathy. Int J Mol Med 15:459–462PubMed
27.
go back to reference Ceriello A, Kumar S, Piconi L, Esposito K, Giugliano D (2007) Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care 30:649–654CrossRefPubMed Ceriello A, Kumar S, Piconi L, Esposito K, Giugliano D (2007) Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care 30:649–654CrossRefPubMed
28.
go back to reference Yim S, Malhotra A, Veves A (2007) Antioxidants and CVD in diabetes: where do we stand now. Curr Diab Rep 7:8–13CrossRefPubMed Yim S, Malhotra A, Veves A (2007) Antioxidants and CVD in diabetes: where do we stand now. Curr Diab Rep 7:8–13CrossRefPubMed
29.
go back to reference Scott JA, King GL (2004) Oxidative stress and antioxidant treatment in diabetes. Ann NY Acad Sci 1031:204–213CrossRefPubMed Scott JA, King GL (2004) Oxidative stress and antioxidant treatment in diabetes. Ann NY Acad Sci 1031:204–213CrossRefPubMed
30.
go back to reference Firoozrai M, Nourbakhsh M, Razzaghy-Azar M (2007) Erythrocyte susceptibility to oxidative stress and antioxidant status in patients with type 1 diabetes. Diabetes Res Clin Pract 77:427–432CrossRefPubMed Firoozrai M, Nourbakhsh M, Razzaghy-Azar M (2007) Erythrocyte susceptibility to oxidative stress and antioxidant status in patients with type 1 diabetes. Diabetes Res Clin Pract 77:427–432CrossRefPubMed
31.
go back to reference Vander Jagt DJ, Harrison JM, Ratliff DM, Hunsaker LA, Vander Jagt DL (2001) Oxidative stress indices in IDDM subjects with and without long-term diabetic complications. Clin Biochem 34:265–270CrossRefPubMed Vander Jagt DJ, Harrison JM, Ratliff DM, Hunsaker LA, Vander Jagt DL (2001) Oxidative stress indices in IDDM subjects with and without long-term diabetic complications. Clin Biochem 34:265–270CrossRefPubMed
32.
33.
34.
go back to reference James RW (2006) A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med 44:1052–1059CrossRefPubMed James RW (2006) A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med 44:1052–1059CrossRefPubMed
35.
go back to reference Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita Y, Arii K, Ito H, Kumon Y, Hashimoto K (1998) Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 47:598–602CrossRefPubMed Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita Y, Arii K, Ito H, Kumon Y, Hashimoto K (1998) Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 47:598–602CrossRefPubMed
36.
go back to reference Wang H, Deng H, Liu W (2002) The effects of paraoxonase-1 and oxidized low density lipoprotein on nephropathy in type-2 diabetes mellitus. Zhonghua Nei Ke Za Zhi 41:179–182PubMed Wang H, Deng H, Liu W (2002) The effects of paraoxonase-1 and oxidized low density lipoprotein on nephropathy in type-2 diabetes mellitus. Zhonghua Nei Ke Za Zhi 41:179–182PubMed
37.
go back to reference Sampson M, Braschi S, Willis G, Astley S (2005) Paraoxonase-1 (PON1) genotype and activity and in vivo oxidised plasma low density lipoprotein [oxLDL] in type 2 diabetes. Clin Sci (Lond) 109:189–197CrossRef Sampson M, Braschi S, Willis G, Astley S (2005) Paraoxonase-1 (PON1) genotype and activity and in vivo oxidised plasma low density lipoprotein [oxLDL] in type 2 diabetes. Clin Sci (Lond) 109:189–197CrossRef
38.
go back to reference Kordonouri O, James RW, Bennetts B, Chan A, Kao YL, Danne T, Silink M, Donaghue K (2001) Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism 50:657–660CrossRefPubMed Kordonouri O, James RW, Bennetts B, Chan A, Kao YL, Danne T, Silink M, Donaghue K (2001) Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism 50:657–660CrossRefPubMed
39.
go back to reference Mackness B, Hine D, McElduff P, Mackness M (2006) High C-reactive protein and low paraoxonase 1 in diabetes as risk factor for coronary heart disease. Atherosclerosis 186:396–401CrossRefPubMed Mackness B, Hine D, McElduff P, Mackness M (2006) High C-reactive protein and low paraoxonase 1 in diabetes as risk factor for coronary heart disease. Atherosclerosis 186:396–401CrossRefPubMed
40.
go back to reference Schalwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, Doni A, van Hinsbergh VW, Stehouwer CD (1999) Concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:351–357CrossRef Schalwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, Doni A, van Hinsbergh VW, Stehouwer CD (1999) Concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:351–357CrossRef
41.
go back to reference Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP (2004) A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18:1450–1452PubMed Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP (2004) A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18:1450–1452PubMed
42.
go back to reference Hayaishi-Okano R, Yamasaki Y, Katakami N, Ohtoshi K, Gorogawa S, Kuroda A, Matsuhisa M, Kosugi K, Nishikawa N, Kajimoto Y, Hori M (2002) Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes. Diabetes Care 25:1432–1438CrossRefPubMed Hayaishi-Okano R, Yamasaki Y, Katakami N, Ohtoshi K, Gorogawa S, Kuroda A, Matsuhisa M, Kosugi K, Nishikawa N, Kajimoto Y, Hori M (2002) Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes. Diabetes Care 25:1432–1438CrossRefPubMed
43.
go back to reference Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G (2005) Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med 22:999–1004CrossRefPubMed Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G (2005) Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med 22:999–1004CrossRefPubMed
44.
go back to reference van Hecke MV, Dekker JM, Nijpels G, Moll AC, Heine RJ, Bouter LM, Polak BC, Stehouwer CD (2005) Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia 48:1300–1306CrossRefPubMed van Hecke MV, Dekker JM, Nijpels G, Moll AC, Heine RJ, Bouter LM, Polak BC, Stehouwer CD (2005) Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia 48:1300–1306CrossRefPubMed
45.
go back to reference Nowak M, Wielkoszyński T, Marek B, Kos-Kudła B, Świętochowska E, Siemińska L, Kajdaniuk D, Głogowska-Szelag J, Nowak K (2008) Blood levels of vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1) and endothelial leukocyte adhesion molecule-1 (ELAM-1) in diabetic retinopathy. Clin and Exp Med 8:159–164CrossRef Nowak M, Wielkoszyński T, Marek B, Kos-Kudła B, Świętochowska E, Siemińska L, Kajdaniuk D, Głogowska-Szelag J, Nowak K (2008) Blood levels of vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1) and endothelial leukocyte adhesion molecule-1 (ELAM-1) in diabetic retinopathy. Clin and Exp Med 8:159–164CrossRef
46.
go back to reference Rifai N, Ridker PM (2003) Population distribution of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. Clin Chem 49:666–669CrossRefPubMed Rifai N, Ridker PM (2003) Population distribution of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. Clin Chem 49:666–669CrossRefPubMed
47.
go back to reference Imhof A, Frohlich M, Loewel H, Helbecque N, Woodward M, Amouyel P, Lowe GD, Koenig W (2003) Distribution of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem 49:669–672CrossRefPubMed Imhof A, Frohlich M, Loewel H, Helbecque N, Woodward M, Amouyel P, Lowe GD, Koenig W (2003) Distribution of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem 49:669–672CrossRefPubMed
48.
go back to reference Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, Nakamura Y, Itoh Y, Kajii E (2001) Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol 153:1183–1190CrossRefPubMed Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, Nakamura Y, Itoh Y, Kajii E (2001) Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol 153:1183–1190CrossRefPubMed
49.
go back to reference Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, Wians FH Jr, Grundy SM, de Lemos JA (2005) Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2:464–469CrossRef Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, Wians FH Jr, Grundy SM, de Lemos JA (2005) Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2:464–469CrossRef
Metadata
Title
Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy
Authors
Mariusz Nowak
Tomasz Wielkoszyński
Bogdan Marek
Beata Kos-Kudła
Elżbieta Świętochowska
Lucyna Siemińska
Jacek Karpe
Dariusz Kajdaniuk
Joanna Głogowska-Szeląg
Katarzyna Nowak
Publication date
01-09-2010
Publisher
Springer Milan
Published in
Clinical and Experimental Medicine / Issue 3/2010
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-009-0084-7

Other articles of this Issue 3/2010

Clinical and Experimental Medicine 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.